AI for Core IT

AI-Driven Cybersecurity for Life Sciences Infrastructure

ANG Associates
Life Sciences & AI Consulting

Nov 2025 6 min read

A Widening Attack Surface for Pharma and Life Sciences

Life sciences companies now sit at the intersection of three of the most valuable and least forgiving categories of data in the modern economy: proprietary R&D intellectual property, regulated clinical trial data, and the operational technology (OT) that runs manufacturing lines. Each of these has become a distinct target. According to IBM's 2026 X-Force Threat Intelligence Index, manufacturing remained the single most targeted industry globally, ahead of financial services and insurance, and exploitation of public-facing applications rose 44 percent year over year as attackers' preferred way in. The same report found 109 distinct ransomware and extortion groups active in 2025, up from 73 the year before, meaning the barrier to launching a credible attack keeps falling even as the number of actors capable of hitting production and R&D environments keeps rising.

The cost of getting this wrong is well documented. IBM's Cost of a Data Breach Report, summarized by HIPAA Journal, found the average healthcare data breach cost $7.42 million in 2025, and healthcare has held the unwelcome title of costliest industry for breaches for 14 consecutive years, taking 279 days on average to identify and contain, roughly five weeks longer than the global average. Pharmaceutical manufacturing has its own cautionary tale: the 2017 NotPetya outbreak hit a major pharmaceutical manufacturer hard enough that CyberScoop reported the resulting damage at more than $310 million, disrupting production for months. Nozomi Networks has separately documented the state-sponsored Winnti campaign infecting multiple pharmaceutical companies, underscoring that both financially motivated and state-linked actors treat this sector as a priority target as IT, IoT, and OT systems grow more interconnected.

What AI-Based Detection Actually Adds

Traditional signature-based tools are built to recognize known threats, which leaves them structurally blind to novel malware and to attackers who use legitimate credentials to move quietly through a network. Machine learning based approaches close part of that gap by learning what "normal" looks like for a given environment, whether that is a scientist's workstation, a clinical data repository, or a programmable logic controller on a fill-finish line, and then flagging statistically significant deviations from that baseline.

Nozomi Networks describes its approach to OT security in pharmaceutical environments as combining "behavior-based anomaly detection and multiple types of signature and rule-based detection," specifically to catch malware communicating with external command-and-control servers or otherwise deviating from established network behavior. Darktrace takes a related approach, applying what it calls Self-Learning AI across enterprise IT, medical IoT, OT, and building management systems at once. Darktrace's own materials note a hard truth about this sector: many connected devices, from infusion pumps to imaging systems, "were never designed with cybersecurity in mind," which is exactly why behavioral baselining rather than signature matching is needed to catch compromise early without disrupting operations.

Anomaly detection flags deviations in network traffic, data movement, or device behavior that fixed rules would miss entirely.
Behavioral analytics profiles normal user and system activity so that credential misuse or lateral movement stands out, which matters given IBM X-Force's finding that identity-based attacks and even AI chatbot credential harvesting (over 300,000 ChatGPT credential sets found for sale in 2025) are accelerating.
Convergence coverage extends the same learning models across IT, IoT, and OT so a single platform can correlate a phishing email with an unusual PLC command rather than treating them as unrelated alerts.

NIS2 and the Swiss Regulatory Backdrop

Regulation is catching up to this risk. Under the EU's NIS2 Directive, DLA Piper's life sciences analysis notes that pharmaceutical manufacturers, clinical research organizations conducting R&D on medicinal products, and in vitro diagnostic device manufacturers are captured as "essential entities" subject to the highest level of supervisory scrutiny, while broader medical device manufacturers fall in as "important entities." Obligations include board-level accountability for cybersecurity risk management, supply chain security assessments, and a strict incident reporting timeline: an early warning within 24 hours, a fuller notification within 72 hours, and a final report within one month for significant incidents. ENISA has since published technical implementation guidance detailing the specific risk management measures organizations must demonstrate, from access control to vulnerability handling.

Switzerland is not an EU member and NIS2 does not apply directly, but its own regulatory direction points the same way. Since April 1, 2025, Switzerland's National Cyber Security Centre (NCSC) has made cyberattack reporting mandatory for operators of critical infrastructure, covering incidents that threaten infrastructure functioning, cause data manipulation or leakage, or involve extortion, with a report due to the NCSC within 24 hours of discovery and full details within 14 days. Enforcement penalties for non-reporting took effect from October 1, 2025, after a six-month grace period. Swiss life sciences companies that supply, partner with, or operate subsidiaries inside the EU increasingly find that meeting NIS2-equivalent controls and Swiss reporting expectations together is simply the price of doing cross-border business, regardless of exactly how a given site is classified.

Where a Delivery Partner Like ANG Associates Fits In

Buying an AI-based detection platform is the easy part. The harder, and more valuable, work is integrating it into a GxP-validated environment without breaking change control, qualifying it so that anomaly-detection alerts hold up under audit, and building the incident response and reporting workflows that NIS2 and Swiss NCSC timelines actually demand. This is where a firm that already sits inside pharma and life sciences IT delivery, rather than a generic security integrator, earns its place: translating a security control into a validated, documented, audit-ready capability that a QA or regulatory affairs team can stand behind.

ANG Associates works precisely at this intersection of AI strategy, GxP compliance and validation, and structured Agile or SAFe delivery for pharma and life sciences organizations. That combination is what turns AI-driven threat detection from a security vendor's roadmap slide into a running, validated, compliant part of a company's clinical, R&D, and manufacturing infrastructure, backed by the IT delivery management discipline needed to keep it that way as NIS2 enforcement matures and Swiss reporting obligations continue to tighten.

Sources

AI cybersecuritylife sciences complianceNIS2 directiveOT security pharmaSwiss information security

Interested in this topic?

Let's discuss how we can apply these approaches to your organization.